OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024
Juliette Paireau, C. Durand, S. Raimbault, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 6
Open Access | Times Cited: 25
Juliette Paireau, C. Durand, S. Raimbault, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 6
Open Access | Times Cited: 25
Showing 25 citing articles:
The recent landscape of RSV vaccine research
Karen Kelleher, N. Subramaniam, Simon B. Drysdale
Therapeutic Advances in Vaccines and Immunotherapy (2025) Vol. 13
Open Access | Times Cited: 1
Karen Kelleher, N. Subramaniam, Simon B. Drysdale
Therapeutic Advances in Vaccines and Immunotherapy (2025) Vol. 13
Open Access | Times Cited: 1
Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season
Olivier Núñez, Carmen Olmedo, David Moreno‐Pérez, et al.
Eurosurveillance (2025) Vol. 30, Iss. 5
Open Access | Times Cited: 1
Olivier Núñez, Carmen Olmedo, David Moreno‐Pérez, et al.
Eurosurveillance (2025) Vol. 30, Iss. 5
Open Access | Times Cited: 1
Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants
Marie-Joëlle Jabagi, Jérémie F. Cohen, Marion Bertrand, et al.
NEJM Evidence (2025) Vol. 4, Iss. 3
Closed Access | Times Cited: 1
Marie-Joëlle Jabagi, Jérémie F. Cohen, Marion Bertrand, et al.
NEJM Evidence (2025) Vol. 4, Iss. 3
Closed Access | Times Cited: 1
Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024)
Matteo Riccò, Antonio Cascio, Silvia Corrado, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 640-640
Open Access | Times Cited: 7
Matteo Riccò, Antonio Cascio, Silvia Corrado, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 640-640
Open Access | Times Cited: 7
Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case–control study in Paris, France
Ricardo Carbajal, Pierre‐Yves Boëlle, Aurélie Pham, et al.
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 10, pp. 730-739
Closed Access | Times Cited: 7
Ricardo Carbajal, Pierre‐Yves Boëlle, Aurélie Pham, et al.
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 10, pp. 730-739
Closed Access | Times Cited: 7
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
Jonne Terstappen, Sarah F Hak, Anant Bhan, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 12, pp. e747-e761
Closed Access | Times Cited: 5
Jonne Terstappen, Sarah F Hak, Anant Bhan, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 12, pp. e747-e761
Closed Access | Times Cited: 5
Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-related Outcomes in Hospital Care Settings: A Seasonal Cohort Study of Infants in Catalonia (Spain)
Aida Perramon‐Malavez, Eduardo Hermosilla, Ermengol Coma, et al.
The Pediatric Infectious Disease Journal (2025)
Closed Access
Aida Perramon‐Malavez, Eduardo Hermosilla, Ermengol Coma, et al.
The Pediatric Infectious Disease Journal (2025)
Closed Access
Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019-2023 national databases: a retrospective study
Denis Sauré, Miguel O’Ryan, Juan Pablo Torres, et al.
Journal of Infection and Public Health (2025) Vol. 18, Iss. 4, pp. 102680-102680
Open Access
Denis Sauré, Miguel O’Ryan, Juan Pablo Torres, et al.
Journal of Infection and Public Health (2025) Vol. 18, Iss. 4, pp. 102680-102680
Open Access
Nirsevimab effectiveness on paediatric emergency visits for RSV bronchiolitis: a test-negative design study
Léa Lenglart, Yaël Levy, Romain Basmaci, et al.
European Journal of Pediatrics (2025) Vol. 184, Iss. 2
Closed Access
Léa Lenglart, Yaël Levy, Romain Basmaci, et al.
European Journal of Pediatrics (2025) Vol. 184, Iss. 2
Closed Access
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season
Roberto Pastor‐Barriuso, Olivier Núñez, Susana Monge
Eurosurveillance (2025) Vol. 30, Iss. 6
Open Access
Roberto Pastor‐Barriuso, Olivier Núñez, Susana Monge
Eurosurveillance (2025) Vol. 30, Iss. 6
Open Access
Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study
Alexis Marouk, B. Verrat, Isabelle Pontais, et al.
European Journal of Pediatrics (2025) Vol. 184, Iss. 3
Closed Access
Alexis Marouk, B. Verrat, Isabelle Pontais, et al.
European Journal of Pediatrics (2025) Vol. 184, Iss. 3
Closed Access
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024
Ushma Wadia, Hannah C. Moore, Peter Richmond, et al.
Journal of Infection (2025), pp. 106466-106466
Open Access
Ushma Wadia, Hannah C. Moore, Peter Richmond, et al.
Journal of Infection (2025), pp. 106466-106466
Open Access
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Hanmeng Xu, Camila Aparicio, Aanchal Wats, et al.
JAMA Network Open (2025) Vol. 8, Iss. 3, pp. e250380-e250380
Open Access
Hanmeng Xu, Camila Aparicio, Aanchal Wats, et al.
JAMA Network Open (2025) Vol. 8, Iss. 3, pp. e250380-e250380
Open Access
Lessons from implementing a long-acting monoclonal antibody (nirsevimab) for RSV in France, Spain and the US
Tim Morris, Karen Y. Pérez Acevedo, Javier Álvarez Aldeán, et al.
Discover Health Systems (2025) Vol. 4, Iss. 1
Open Access
Tim Morris, Karen Y. Pérez Acevedo, Javier Álvarez Aldeán, et al.
Discover Health Systems (2025) Vol. 4, Iss. 1
Open Access
Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study
Slim Fourati, Alawiya Reslan, Jérôme Bourret, et al.
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 3
Slim Fourati, Alawiya Reslan, Jérôme Bourret, et al.
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 3
Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization
Alice Shanklin, Taylor Olson, Anita Patel, et al.
JAMA Network Open (2024) Vol. 7, Iss. 10, pp. e2440997-e2440997
Open Access | Times Cited: 1
Alice Shanklin, Taylor Olson, Anita Patel, et al.
JAMA Network Open (2024) Vol. 7, Iss. 10, pp. e2440997-e2440997
Open Access | Times Cited: 1
Bronchiolite : stratégie de prévention pour l’hiver 2024–2025
Agnès Linglart, Romain Basmaci, Hervé Haas, et al.
Perfectionnement en Pédiatrie (2024) Vol. 7, Iss. 3, pp. 151-152
Closed Access
Agnès Linglart, Romain Basmaci, Hervé Haas, et al.
Perfectionnement en Pédiatrie (2024) Vol. 7, Iss. 3, pp. 151-152
Closed Access
Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study
Hanmeng Xu, C. Aparicio, Aanchal Wats, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Hanmeng Xu, C. Aparicio, Aanchal Wats, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Le pharmacien, un acteur clé dans la lutte contre le virus respiratoire syncytial
Marion Nexon
Actualités Pharmaceutiques (2024) Vol. 63, Iss. 639, pp. 35-39
Closed Access
Marion Nexon
Actualités Pharmaceutiques (2024) Vol. 63, Iss. 639, pp. 35-39
Closed Access
First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants.
Andrea Orsi, Marianna Scarpaleggia, Vincenzo Baldo, et al.
PubMed (2024) Vol. 65, Iss. 2, pp. E172-E187
Closed Access
Andrea Orsi, Marianna Scarpaleggia, Vincenzo Baldo, et al.
PubMed (2024) Vol. 65, Iss. 2, pp. E172-E187
Closed Access
Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel
Bosco Paes, Vivien Brown, Erin Courtney, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
Bosco Paes, Vivien Brown, Erin Courtney, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
Changes in Respiratory Syncytial Virus‐Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France
Cécile Chauvel, Côme Horvat, Étienne Javouhey, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 12
Open Access
Cécile Chauvel, Côme Horvat, Étienne Javouhey, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 12
Open Access
Independent Analysis of the Results of the First Infant Immunization Campaign with Beyfortus® (Nirsevimab, Monoclonal Antibody Against RSV Bronchiolitis Virus): Mixed Results, Identification of Biases, and Possible Role and Mechanisms of ADE (Antibody Dependent Enhancement)
Hélène Banoun
(2024)
Open Access
Hélène Banoun
(2024)
Open Access
Nirsevimab: Alleviating the burden of RSV morbidity in young children
Marcus Wing Choy Loe, Helen Soenong, Evelyn Lee, et al.
Journal of Paediatrics and Child Health (2024) Vol. 60, Iss. 10, pp. 489-498
Open Access
Marcus Wing Choy Loe, Helen Soenong, Evelyn Lee, et al.
Journal of Paediatrics and Child Health (2024) Vol. 60, Iss. 10, pp. 489-498
Open Access
Nirsevimab—a breakthrough in respiratory syncytial virus bronchiolitis
Zein Assad, Jesse Papenburg, Naïm Ouldali
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 10, pp. 708-709
Closed Access
Zein Assad, Jesse Papenburg, Naïm Ouldali
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 10, pp. 708-709
Closed Access
